Literature DB >> 10992300

Karyotypic characterization of urinary bladder transitional cell carcinomas.

I Fadl-Elmula1, L Gorunova, N Mandahl, P Elfving, R Lundgren, F Mitelman, S Heim.   

Abstract

Samples from 34 primary transitional cell carcinomas (TCCs) of the bladder were short-term-cultured and processed for cytogenetic analysis after G-banding of the chromosomes. Clonal chromosome abnormalities were detected in 27 tumors and normal karyotypes in 3, and the cultures from 4 tumors failed to grow. Losses of genetic material were more common than gains, indicating that loss of tumor suppressor genes may be of major importance in TCC pathogenesis. There was no clonal heterogeneity within individual tumors, consonant with the view that TCCs are monoclonal in origin. The most striking finding was the involvement of chromosome 9 in 92% of the informative cases, as numerical loss of one chromosome copy in 15 cases, but as structural rearrangement in 8. The changes in chromosome 9 always led to loss of material; from 9p, from 9q, or of the entire chromosome. A total of 16 recurrent, unbalanced structural rearrangements were seen, of which del(1)(p11), add(3)(q21), add(5)(q11), del(6)(q13), add(7)(q11), add(11)(p11), i(13)(q10), del(14)(q24), and i(17)(q10) are described here for the first time. The karyotypic imbalances were dominated by losses of the entire or parts of chromosome arms 1p, 9p, 9q, 11p, 13p, and 17p, loss of an entire copy of chromosomes 9, 14, 16, 18, and the Y chromosome, and gains of chromosome arms 1q and 13q and of chromosomes 7 and 20. The chromosome bands and centomeric breakpoints preferentially involved in structural rearrangements were 1q12, 2q11, 5q11, 8q24, 9p13, 9q13, 9q22, 11p11, and 13p10. Rearrangements of 17p and the formation of an i(5)(p10) were associated with more aggressive tumor phenotypes. There was also a general correlation between the tumors' grade/stage and karyotypic complexity, indicating that progressive accumulation of acquired genetic alterations is the driving force behind multistep bladder TCC carcinogenesis. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2000        PMID: 10992300

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  9 in total

1.  An hTERT-immortalized human urothelial cell line that responds to anti-proliferative factor.

Authors:  Jayoung Kim; Mihee Ji; Joseph A DiDonato; Raymond R Rackley; Mei Kuang; Provash C Sadhukhan; Joshua R Mauney; Susan K Keay; Michael R Freeman; Louis S Liou; Rosalyn M Adam
Journal:  In Vitro Cell Dev Biol Anim       Date:  2010-12-07       Impact factor: 2.416

Review 2.  Molecular pathogenesis of bladder cancer.

Authors:  Margaret A Knowles
Journal:  Int J Clin Oncol       Date:  2008-08-15       Impact factor: 3.402

Review 3.  Sexual dimorphism in cancer.

Authors:  Andrea Clocchiatti; Elisa Cora; Yosra Zhang; G Paolo Dotto
Journal:  Nat Rev Cancer       Date:  2016-04-15       Impact factor: 60.716

4.  Chromosomal changes in uroepithelial carcinomas.

Authors:  Imad Fadl-Elmula
Journal:  Cell Chromosome       Date:  2005-08-07

5.  Destabilization of chromosome 9 in transitional cell carcinoma of the urinary bladder.

Authors:  F Kimura; A R Florl; H H Seifert; J Louhelainen; S Maas; M A Knowles; W A Schulz
Journal:  Br J Cancer       Date:  2001-12-14       Impact factor: 7.640

Review 6.  SLC14A1: a novel target for human urothelial cancer.

Authors:  R Hou; X Kong; B Yang; Y Xie; G Chen
Journal:  Clin Transl Oncol       Date:  2017-06-06       Impact factor: 3.405

7.  X chromosome protects against bladder cancer in females via a KDM6A-dependent epigenetic mechanism.

Authors:  Satoshi Kaneko; Xue Li
Journal:  Sci Adv       Date:  2018-06-13       Impact factor: 14.136

Review 8.  Gender Differences in Urothelial Bladder Cancer: Effects of Natural Killer Lymphocyte Immunity.

Authors:  Charles T Lutz; Lydia Livas; Steven R Presnell; Morgan Sexton; Peng Wang
Journal:  J Clin Med       Date:  2021-11-04       Impact factor: 4.964

9.  UroVysion fluorescence in situ hybridization (UroVysion FISH) assay for detection of bladder cancer in voided urine of Turkish patients: a preliminary study.

Authors:  Yavuz Dodurga; Cığır Biray Avcı; Sunde Yılmaz; Oktay Nazlı; Ozgür Coğulu; Tufan Cankaya; Cumhur Gündüz
Journal:  Contemp Oncol (Pozn)       Date:  2013-04-29
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.